Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**NCTF 135 HA** is a sterile, injectable polyrevitalizing solution developed for mesotherapy and aesthetic indications. It contains non-crosslinked hyaluronic acid (5 mg/mL) combined with a blend of 59 active ingredients, including vitamins, amino acids, minerals, nucleotides, coenzymes, and antioxidants. Designed for injection into the dermis of the face, neck, and décolleté, its primary purpose is to deliver hydration, promote skin redensification, improve skin radiance, texture, and elasticity, and reduce superficial wrinkles associated with aging. Hyaluronic acid acts to hydrate and plump skin, while the cocktail of nutrients stimulates collagen and elastin synthesis, promotes cell regeneration, protects against oxidative stress, and supports the extracellular matrix. NCTF 135 HA is considered a first-generation skin booster and mesotherapy agent, with clinically demonstrated efficacy in wrinkle reduction, increased skin hydration, and improvements in skin density and self-esteem. It is not indicated for disease treatment, but for cosmetic and anti-aging skin revitalization in adults over 18 years[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NCTF 135 HA.